Good MorningEquity markets retreated on Thursday after a hot reading of the Produce Price Index raised fears that higher-for-longer means what it sounds like. The PPI accelerated at the core and headline levels, suggesting that consumer-level inflation will remain hot. In this environment, it is unlikely the FOMC will cut rates before mid-summer, and the first cut may not come until late in the year.
The risk for markets is the outlook for earnings. The market has priced in a significant upswing in earnings power for the back half of 2024 that may not come. This has the market set up for a correction that could be severe, given the proper stimulus. The catalyst for the correction may be in the earnings forecasts, which are expected to fall from their current levels. With only a few weeks left until the start of Q1 reporting, it is possible that the catalyst could come soon. Featured: Watch former hedge fund manager place this trade live (DTI) 
|
Stocks | | |
You've undoubtedly seen the headlines covering cryptocurrencies as they soar to highs or violently crash to lows. Hardly a day goes by without some news about cryptocurrency as celebrities, athletes, actors and influencers have gotten into the fray. While they have become mainstream as a topic, ma... Read the Full Story |
|
From Our PartnersThere is a recession-proof company that is poised to grow in the coming years. Our research team has given them our highest score as a solid addition to any portfolio.
By clicking link you are subscribing to The Darwin Investor Network and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.
| | Download The Full Report Here for Free |
|
Stocks | | |
When geopolitical tensions rise, defense contractor stocks often surge in response. These stocks are sensitive to international conflicts and national security developments, making them potent investment options. Here’s a deeper dive into what defense stocks are and how you can wisely invest... Read the Full Story |
|
Stocks | | |
Dell Technologies Inc (NYSE: DELL), The Trade Desk Inc. (NASDAQ: TTD) and Apollo Global Management Inc. (NYSE: APO) represent a diverse group of companies but have something in common: They're large-cap stocks that aren’t part of the S&P 500 but are outperforming the index.
... Read the Full Story |
|
From Our PartnersThe World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! | | | | Get the name of the stock here |
|
Markets | | |
Analysts' activity in Q1 is robust, with results from Q4 outpacing estimates and guidance for tech stocks at least, leading them to raise their targets. As active as the analysts have been, the market leaders and the stocks getting the most upgrades remain the same. The rankings have been juggled,... Read the Full Story |
|
Stocks | | | Wall Street closed out its second straight losing week Friday, giving back some of the gains that helped push the stock market to an all-time high earlier in the week. The S&P 500 fell 0.6%, its third straight loss. The benchmark index hit a record high on Tuesday, but mostly wavered in the days... Read the Full Story |
|
From Our PartnersAs March unfolds, the investment horizon brims with opportunity. Don't miss out on the chance to elevate your portfolio with our expertly curated list of 5 stocks. These picks are not just promising; they're positioned to potentially deliver substantial returns in the dynamic market landscape of 2024.
With a keen eye on innovation and growth potential, our selection is designed to secure your spot at the forefront of this month's investment wave. Act now to gain exclusive access to these high-potential stocks and watch your investments thrive. Time is of the essence - secure your financial future today! | | Click here to unveil the stocks that are set to soar. |
|
Markets | | |
For a stock that has led its peers for so long, Southwest Airlines Company (NYSE: LUV) has been having a tough time recently. While it was able to catch some of those gains that have been sweeping across equities since November, this week’s 20% drop has given up much of t... Read the Full Story |
|
Markets | | | China’s markets regulator on Friday renewed its efforts to pep up the stock market, pledging to raise the quality of companies listed on domestic markets. The China Securities Regulatory Commission issued draft guidelines to more strictly vet applications for share listings and to more closely overs... Read the Full Story |
|
Markets | | | A 2023 report from investment firm Vanguard estimates that about a quarter of Americans age 60 and over could move to a cheaper housing market and use the equity in their homes to upsize their retirement savings — making retirement more secure and enjoyable Read the Full Story |
|
Markets | | | Americans picked up their spending a bit in February after pulling back the previous month. But last month’s gain was weaker than expected, and January’s decline was revised even lower, suggesting that many are growing more cautious with their money.Retail sales rose 0.6% last month after falling a ... Read the Full Story |
|
Markets | | | Lori Shelton can't fathom ever having the money to buy a home — and that's a major reason why so many voters feel down on the economy ahead of this year's presidential election.Shelton, 67, drives an Uber to help pay rent in Aurora, Colorado. An advance on her pay covered her apartment's security de... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC. | | View Today's Stock Pick |
|
